Loading...

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

The development of acquired resistance to osimertinib (Osim) (AZD9291 or TAGRISSO(TM)), an FDA‐approved third‐generation epidermal growth factor receptor (EGFR) inhibitor for the treatment of EGFR‐mutant nonsmall cell lung cancer (NSCLC), limits the long‐term benefits for patients. Thus, effective t...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mol Oncol
Main Authors: Zang, Hongjing, Qian, Guoqing, Arbiser, Jack, Owonikoko, Taofeek K., Ramalingam, Suresh S., Fan, Songqing, Sun, Shi‐Yong
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2020
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7138398/
https://ncbi.nlm.nih.gov/pubmed/32003107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12645
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!